JP2022535955A5 - - Google Patents

Info

Publication number
JP2022535955A5
JP2022535955A5 JP2021573380A JP2021573380A JP2022535955A5 JP 2022535955 A5 JP2022535955 A5 JP 2022535955A5 JP 2021573380 A JP2021573380 A JP 2021573380A JP 2021573380 A JP2021573380 A JP 2021573380A JP 2022535955 A5 JP2022535955 A5 JP 2022535955A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
disease
substituted
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021573380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535955A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/066196 external-priority patent/WO2020249669A1/en
Publication of JP2022535955A publication Critical patent/JP2022535955A/ja
Publication of JP2022535955A5 publication Critical patent/JP2022535955A5/ja
Pending legal-status Critical Current

Links

JP2021573380A 2019-06-12 2020-06-11 スルホンアミド誘導体及びその使用 Pending JP2022535955A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962860661P 2019-06-12 2019-06-12
US62/860,661 2019-06-12
PCT/EP2020/066196 WO2020249669A1 (en) 2019-06-12 2020-06-11 Sulfonamide derivatives and uses thereof

Publications (2)

Publication Number Publication Date
JP2022535955A JP2022535955A (ja) 2022-08-10
JP2022535955A5 true JP2022535955A5 (cg-RX-API-DMAC7.html) 2023-06-19

Family

ID=71108564

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573380A Pending JP2022535955A (ja) 2019-06-12 2020-06-11 スルホンアミド誘導体及びその使用

Country Status (5)

Country Link
US (1) US20220267300A1 (cg-RX-API-DMAC7.html)
EP (1) EP3983388A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022535955A (cg-RX-API-DMAC7.html)
CN (1) CN114761383A (cg-RX-API-DMAC7.html)
WO (1) WO2020249669A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
HUE067378T2 (hu) 2019-06-12 2024-10-28 Nodthera Ltd Szulfonilurea származékok és alkalmazásaik
JP7661248B2 (ja) 2019-06-12 2025-04-14 ノッドセラ リミテッド スルホニル尿素誘導体及びその使用
EP4559461A1 (en) * 2023-11-22 2025-05-28 Servicio Andaluz De Salud Dual nlrp1 and nlrp3 inhibitors for use as a medicament

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA903210A (en) * 1970-02-03 1972-06-20 Merck Sharp And Dohme (I.A.) Corp. Indole derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CZ36294A3 (en) * 1991-08-19 1994-07-13 Du Pont Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
CZ36394A3 (en) * 1991-08-19 1994-07-13 Du Pont Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
AU7782694A (en) * 1993-09-28 1995-04-18 Ciba-Geigy Ag Acylated sulphonamides as insecticides and acaricides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
AR039156A1 (es) * 2002-03-28 2005-02-09 Novartis Ag Amidas del acido piperidinilamino sulfamico o piperazinil sulfamico y su uso para la manufactura de un medicamento en enfermedades mediadas por la accion de la sulfatasa esteroide
JP6929792B2 (ja) * 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
PL3359541T3 (pl) * 2015-10-09 2021-01-11 AbbVie Overseas S.à r.l. N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA
BR112018016671A2 (pt) * 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
US11447460B2 (en) * 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
EP3272739A1 (en) * 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
EP3634951B8 (en) * 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
GB201721185D0 (en) * 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
SG11202101480XA (en) * 2018-08-15 2021-03-30 Inflazome Ltd Novel sulfonamideurea compounds
GB201902327D0 (en) * 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds

Similar Documents

Publication Publication Date Title
US20220169628A1 (en) Therapeutic agents and methods of treatment
JP2022536160A5 (cg-RX-API-DMAC7.html)
JP6125614B2 (ja) ピロロベンゾジアゼピン
JP2023540733A5 (cg-RX-API-DMAC7.html)
ES2905318T3 (es) Profármacos de riluzol y su uso
JP2021522276A5 (cg-RX-API-DMAC7.html)
FI3728238T3 (fi) Sulfonyyliureajohdannaisia nlrp3-inflammasomin moduulaattoreina
JP2018531289A5 (cg-RX-API-DMAC7.html)
RU2018105549A (ru) Производные бензодиазепина как ингибиторы rsv
JP2022507506A5 (cg-RX-API-DMAC7.html)
WO2013138753A1 (en) Prodrugs of riluzole and their method of use
JP2022535956A5 (cg-RX-API-DMAC7.html)
JP6938376B2 (ja) 多剤耐性菌に有効な新規アミノグリコシド抗生物質
ES2983661T3 (es) Derivados de sulfonilurea y usos de los mismos
JP2022507505A5 (cg-RX-API-DMAC7.html)
TW202329933A (zh) 咪唑并嗒𠯤il—17抑制劑化合物(一)
WO2023211940A1 (en) Sting agonists, formulations, and uses thereof
JP2023500662A (ja) イタコネートおよびメチルイタコネートの新規プロドラッグ
JP2022518526A5 (cg-RX-API-DMAC7.html)
KR102388412B1 (ko) 페노티아진 유도체 및 이의 사용 방법
JP2025504374A5 (cg-RX-API-DMAC7.html)
US8871983B2 (en) Lipid compounds for suppression of tumorigenesis
RU2023108168A (ru) Производные сульфамоилмочевины, содержащие алкилоксациклоалкильную группу, и их применения
US20130296348A1 (en) Bis-Quinazoline Derivatives as Inhibitors for Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase
JP2020536860A (ja) 増殖性疾患、感染症、アレルギー、炎症及び/又は喘息を治療するためのtctp阻害剤